Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|110-115

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 110-115

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP

By  

Current Cancer Drug Targets, Vol. 14, Iss. 7, 2014-09 ,pp. : 659-670

Bentham Science Publishers

Access to resources Recommend Favorite

R-CHOP economically dominant over CHOP in DLBCL

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 544, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

R-CHOP economically dominant over CHOP in DLBCL

By  

Inpharma, Vol. 1, Iss. 1619, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

By  

Cancer, Vol. 121, Iss. 14, 2015-07 ,pp. : 2375-2382

Blackwell Publishing

Access to resources Recommend Favorite

A CHOP regimen is effective for post-transplant lymphoproliferative disorders (PTLD) that have progressed after first-line therapy with rituximab

By  

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite